Tumour suppressor gene signature predicts early progression in metastatic hormone-sensitive metastatic prostate cancer (mHSPC) patients

被引：0

作者：

Garcia De Herreros, M. ^{[1
]}

Jimenez Blasco, N. ^{[2
]}

Reig Torras, O. ^{[1
]}

Ferrer Mileo, L. ^{[1
]}

Aversa, C. ^{[1
]}

Garcia-Esteve, S. ^{[2
]}

Rodriguez-Carunchio, L. ^{[3
]}

Trias Puigsureda, I. ^{[3
]}

Padrosa, J. ^{[1
]}

Fernandez Manas, L. ^{[1
]}

Marin, M. ^{[2
]}

Font Pous, A. ^{[4
]}

Rodriguez-Vida, A. ^{[5
]}

Climent Duran, M. A. ^{[6
]}

Cros Costa, S. ^{[7
]}

Chirivella Gonzalez, I. ^{[8
]}

Figols Gorina, M. ^{[9
]}

Mellado Gonzalez, B. ^{[1
]}

机构：

[1] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain

[2] IDIBAPS Fundacio Recerca Clin Barcelona, Translat Genom & Targeted Therapeut Solid Tumors, Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain

[3] Hosp Clin Barcelona, Dept Pathol, Barcelona, Spain

[4] Hosp Badalona Germans Trias & Pujol, Dept Oncol, ICO Inst Catala Oncol Badalona, Barcelona, Spain

[5] Hosp del Mar Parc Salut Mar, Dept Med Oncol, Barcelona, Spain

[6] IVO Fdn Inst Valenciano Oncol, Med Oncol, Valencia, Spain

[7] Hosp Gen Granollers, Dept Med Oncol, Granollers, Spain

[8] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain

[9] Xarxa Assistencial Univ Manresa, Hosp St Joan Deu Althaia, Med Oncol, Manresa, Spain

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.1726

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1645P

引用

页码：S992 / S992

页数：1

共 50 条

[1] TITAN study: evaluation of apalutamide in patients with metastatic hormone-sensitive prostate cancer - Treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
Merseburger, Axel S.
Suttmann, Henrik
AKTUELLE UROLOGIE, 2021, 52 (02) : 155 - 160
[2] Use of abiraterone for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Cathomas, R.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 130 - 130
[3] DISEASE BURDEN OF METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) IN CHINA
Yu, M.
Duan, X.
Wang, J.
Zhang, X. J.
Yu, F.
VALUE IN HEALTH, 2021, 24 : S39 - S40
[4] Recent developments in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
Schwentner, Christian
AKTUELLE UROLOGIE, 2022, 53 (01) : 31 - 36
[5] Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm
Weiner, Adam B.
Nettey, Oluwarotimi S.
Morgans, Alicia K.
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (09)
[6] IDENTIFYING AND CHARACTERIZING METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) POPULATION IN FINLAND
Ruotsalainen, J.
Korhonen, M. J.
Purmonen, T.
Joutseno, J.
Saavuori, N.
VALUE IN HEALTH, 2023, 26 (12) : S535 - S535
[7] Prognostic value of germline mutations in metastatic hormone-sensitive prostate cancer (mHSPC)
Custodio-Cabello, Sara
Pacheco-Barcia, Vilma
Palka-Kotlowska, Magda
Fernandez-Hernandez, Laura
Del Alamo, Julio Fernandez
Oliveros-Acebes, Eduardo
Cabezon-Gutierrez, Luis
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 (10) : 331e13 - 331e24
[8] Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm
Adam B. Weiner
Oluwarotimi S. Nettey
Alicia K. Morgans
Current Treatment Options in Oncology, 2019, 20
[9] Metastatic hormone-sensitive prostate cancer
Gravis, Gwenaelle
Salem, Naji
Walz, Jochen
BULLETIN DU CANCER, 2015, 102 (01) : 57 - 64
[10] AUO First-line Therapy for metastatic hormone-sensitive Prostate Cancer (mHSPC)
Rexer, H.
Feyerabend, S.
Graefen, M.
UROLOGIE, 2023, 62 (04): : 441 - 442

← 1 2 3 4 5 →